Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 - PubMed (original) (raw)
. 1993 Apr 29;362(6423):857-60.
doi: 10.1038/362857a0.
Affiliations
- PMID: 8479525
- DOI: 10.1038/362857a0
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
J D Oliner et al. Nature. 1993.
Abstract
The tumour-suppressor gene p53 is inactivated in most human malignancies either by missense mutations or by binding to oncogenic proteins. In human soft tissue sarcomas, inactivation apparently results from MDM2 gene amplification. MDM2 is an oncogene product that may function by binding to p53 and inhibiting its ability to activate transcription. Here we show that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain. The isolated p53 activation domain fused to another DNA-binding protein is also inactivated by MDM2, confirming that MDM2 can inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery.
Similar articles
- The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
Brown DR, Deb D, Frum R, Hickes L, Munoz R, Deb S, Deb SP. Brown DR, et al. Int J Oncol. 2001 Mar;18(3):449-59. doi: 10.3892/ijo.18.3.449. Int J Oncol. 2001. PMID: 11179471 - The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
Brown DR, Deb S, Muñoz RM, Subler MA, Deb SP. Brown DR, et al. Mol Cell Biol. 1993 Nov;13(11):6849-57. doi: 10.1128/mcb.13.11.6849-6857.1993. Mol Cell Biol. 1993. PMID: 8413278 Free PMC article. - Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.
Juven T, Barak Y, Zauberman A, George DL, Oren M. Juven T, et al. Oncogene. 1993 Dec;8(12):3411-6. Oncogene. 1993. PMID: 8247544 - The mdm2 proto-oncogene.
Haines DS. Haines DS. Leuk Lymphoma. 1997 Jul;26(3-4):227-38. doi: 10.3109/10428199709051772. Leuk Lymphoma. 1997. PMID: 9322885 Review. - [Mdm2, p53 and the cell cycle: when well enough is best left alone].
Maréchal V. Maréchal V. Pathol Biol (Paris). 1997 Dec;45(10):824-32. Pathol Biol (Paris). 1997. PMID: 9769946 Review. French.
Cited by
- Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex.
Miller Jenkins LM, Feng H, Durell SR, Tagad HD, Mazur SJ, Tropea JE, Bai Y, Appella E. Miller Jenkins LM, et al. Biochemistry. 2015 Mar 24;54(11):2001-10. doi: 10.1021/acs.biochem.5b00044. Epub 2015 Mar 16. Biochemistry. 2015. PMID: 25753752 Free PMC article. - Cancer-Associated Mutations Perturb the Disordered Ensemble and Interactions of the Intrinsically Disordered p53 Transactivation Domain.
Schrag LG, Liu X, Thevarajan I, Prakash O, Zolkiewski M, Chen J. Schrag LG, et al. J Mol Biol. 2021 Jul 23;433(15):167048. doi: 10.1016/j.jmb.2021.167048. Epub 2021 May 11. J Mol Biol. 2021. PMID: 33984364 Free PMC article. - Targeting protein-protein interfaces using macrocyclic peptides.
Gao M, Cheng K, Yin H. Gao M, et al. Biopolymers. 2015 Jul;104(4):310-6. doi: 10.1002/bip.22625. Biopolymers. 2015. PMID: 25664609 Free PMC article. Review. - Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress.
Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Zhou X, et al. Oncogene. 2013 Jan 17;32(3):388-96. doi: 10.1038/onc.2012.63. Epub 2012 Mar 5. Oncogene. 2013. PMID: 22391559 Free PMC article. - Directed evolution of highly selective proteases by using a novel FACS-based screen that capitalizes on the p53 regulator MDM2.
Yoo TH, Pogson M, Iverson BL, Georgiou G. Yoo TH, et al. Chembiochem. 2012 Mar 19;13(5):649-53. doi: 10.1002/cbic.201100718. Epub 2012 Feb 14. Chembiochem. 2012. PMID: 22334509 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous